Literature DB >> 30515838

IL-27 signaling deficiency develops Th17-enhanced Th2-dominant inflammation in murine allergic conjunctivitis model.

Xin Chen1,2, Ruzhi Deng1,2, Wei Chi2,3, Xia Hua2, Fan Lu1, Fang Bian2, Ning Gao2, Zhijie Li4, Stephen C Pflugfelder2, Cintia S de Paiva2, De-Quan Li2.   

Abstract

BACKGROUND: While most studies focus on pro-allergic cytokines, the protective role of immunosuppressive cytokines in allergic inflammation is not well elucidated. This study was to explore a novel anti-inflammatory role and cellular/molecular mechanism of IL-27 in allergic inflammation.
METHODS: A murine model of experimental allergic conjunctivitis (EAC) was induced in BALB/c, C57BL/6 or IL-27Rα-deficient (WSX-1-/- ) mice by short ragweed pollen, with untreated or PBS-treated mice as controls. The serum, eyeballs, conjunctiva, cervical lymph nodes (CLNs) were used for study. Gene expression was determined by RT-qPCR, and protein production and activation were evaluated by immunostaining, ELISA and Western blotting.
RESULTS: Typical allergic manifestations and stimulated thymic stromal lymphopoietin (TSLP) signaling and Th2 responses were observed in ocular surface of EAC models in BALB/c and C57BL/6 mice. The decrease of IL-27 at mRNA (IL-27/EBI3) and protein levels were detected in serum, conjunctiva and CLN, as evaluated by RT-qPCR, immunofluorescent staining, ELISA and Western blotting. EAC induced in WSX-1-/- mice showed aggravated allergic signs with higher TSLP-driven Th2-dominant inflammation, accompanied by stimulated Th17 responses, including IL-17A, IL-17F, and transcription factor RORγt. In contrast, Th1 cytokine IFNγ and Treg marker IL-10, with their respective transcription factors T-bet and foxp3, were largely suppressed. Interestingly, imbalanced activation between reduced phosphor (P)-STAT1 and stimulated P-STAT6 were revealed in EAC, especially WSX-1-/- -EAC mice.
CONCLUSION: These findings demonstrated a natural protective mechanism by IL-27, of which signaling deficiency develops a Th17-type hyperresponse that further aggravates Th2-dominant allergic inflammation.
© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  IL-27; Th17; Th2; allergy; anti-inflammatory cytokine

Mesh:

Substances:

Year:  2019        PMID: 30515838      PMCID: PMC7190079          DOI: 10.1111/all.13691

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  45 in total

1.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

2.  IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells.

Authors:  Raphael Schneider; Teodora Yaneva; Diane Beauseigle; Lama El-Khoury; Nathalie Arbour
Journal:  Eur J Immunol       Date:  2010-12-09       Impact factor: 5.532

3.  ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells.

Authors:  Cintia S de Paiva; Zhuo Chen; Rosa M Corrales; Stephen C Pflugfelder; De-Quan Li
Journal:  Stem Cells       Date:  2005       Impact factor: 6.277

4.  A novel murine model of allergic conjunctivitis.

Authors:  M T Magone; C C Chan; L V Rizzo; A T Kozhich; S M Whitcup
Journal:  Clin Immunol Immunopathol       Date:  1998-04

5.  IL-33: a novel danger signal system in atopic dermatitis.

Authors:  Ferda Cevikbas; Martin Steinhoff
Journal:  J Invest Dermatol       Date:  2012-05       Impact factor: 8.551

Review 6.  Advances in understanding the anti-inflammatory properties of IL-27.

Authors:  J S Stumhofer; C A Hunter
Journal:  Immunol Lett       Date:  2008-03-03       Impact factor: 3.685

7.  Close relationship between T helper (Th)17 and Th2 response in murine allergic contact dermatitis.

Authors:  A Matsushita; M Seike; T Hagiwara; A Sato; H Ohtsu
Journal:  Clin Exp Dermatol       Date:  2014-09-05       Impact factor: 3.470

8.  Decreased serum interleukin 27 in Brazilian systemic lupus erythematosus patients.

Authors:  Angela Luzia Branco Pinto Duarte; Andréa Tavares Dantas; Henrique de Ataíde Mariz; Flaviana Alves dos Santos; Juliana Cruz da Silva; Laurindo Ferreira da Rocha; Suely Lins Galdino; Maira Galdino da Rocha Pitta
Journal:  Mol Biol Rep       Date:  2013-05-06       Impact factor: 2.316

9.  In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis.

Authors:  Su-Jin Moon; Jin-Sil Park; Yu-Jung Heo; Chang-Min Kang; Eun-Kyung Kim; Mi-Ae Lim; Jun-Geol Ryu; Seong Jeong Park; Kyung Su Park; Young-Chul Sung; Sung-Hwan Park; Ho-Youn Kim; Jun-Ki Min; Mi-La Cho
Journal:  Exp Mol Med       Date:  2013-10-04       Impact factor: 8.718

10.  Blueberry Component Pterostilbene Protects Corneal Epithelial Cells from Inflammation via Anti-oxidative Pathway.

Authors:  Jin Li; Xia Hua; Lili Zhang; Fan Lu; Terry G Coursey; Stephen C Pflugfelder; De-Quan Li
Journal:  Sci Rep       Date:  2016-01-14       Impact factor: 4.379

View more
  11 in total

1.  Short ragweed pollen promotes M2 macrophage polarization via TSLP/TSLPR/OX40L signaling in allergic inflammation.

Authors:  Ruzhi Deng; Xin Chen; Yun Zhang; Fang Bian; Ning Gao; Jiaoyue Hu; Changjun Wang; Rodrigo G de Souza; Fan Lu; Stephen C Pflugfelder; De-Quan Li
Journal:  Mucosal Immunol       Date:  2019-07-26       Impact factor: 7.313

Review 2.  Immune responses to injury and their links to eye disease.

Authors:  Mary Ann Stepp; A Sue Menko
Journal:  Transl Res       Date:  2021-05-27       Impact factor: 10.171

3.  The Inhibition of Group II Innate Lymphoid Cell Response by IL-27 in Allergic Rhinitis.

Authors:  Xi Luo; Qingxiang Zeng; Yan Li; Yiquan Tang; Wenlong Liu; Renzhong Luo
Journal:  J Immunol Res       Date:  2020-12-16       Impact factor: 4.818

4.  Endometrial Regenerative Cell-Derived Conditioned Medium Alleviates Experimental Colitis.

Authors:  Chenglu Sun; Jingpeng Hao; Hong Qin; Yanglin Zhu; Xiang Li; Baoren Zhang; Yafei Qin; Guangming Li; Hongda Wang; Hao Wang
Journal:  Stem Cells Int       Date:  2022-01-27       Impact factor: 5.443

5.  MiR-146a upregulates FOXP3 and suppresses inflammation by targeting HIPK3/STAT3 in allergic conjunctivitis.

Authors:  Hui Guo; Yongxin Zhang; Zifang Liao; Wenzhu Zhan; Yuan Wang; Yun Peng; Meina Yang; Xudai Ma; Guogan Yin; Lin Ye
Journal:  Ann Transl Med       Date:  2022-03

6.  The Protective Effects of KAT5 Inhibition on Ocular Inflammation by Mediating the PI3K/AKT Pathway in a Murine Model of Allergic Conjunctivitis.

Authors:  Fei Luo; Yu Tao; Mengyu Wang; Liuqing Yang; Ruifeng Su; Zhiqiang Pan; Xiaobo Tan
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-05-02       Impact factor: 4.799

7.  Investigation of Sensitization Potential of the Soybean Allergen Gly m 4 by Using Caco-2/Immune Cells Co-Culture Model.

Authors:  Ivan V Bogdanov; Ekaterina I Finkina; Daria N Melnikova; Rustam H Ziganshin; Tatiana V Ovchinnikova
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

8.  IL-27 Regulated CD4+IL-10+ T Cells in Experimental Sjögren Syndrome.

Authors:  Jingjing Qi; Zhuoya Zhang; Xiaojun Tang; Wenchao Li; Weiwei Chen; Genhong Yao
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

9.  Differentially Expressed Gene Pathways in the Conjunctiva of Sjögren Syndrome Keratoconjunctivitis Sicca.

Authors:  Cintia S de Paiva; Claudia M Trujillo-Vargas; Laura Schaefer; Zhiyuan Yu; Robert A Britton; Stephen C Pflugfelder
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

10.  Identification of the correlations between interleukin-27 (IL-27) and immune-inflammatory imbalance in preterm birth.

Authors:  Yuxin Ran; Dongni Huang; Youwen Mei; Zheng Liu; Yunqian Zhou; Jie He; Hanwen Zhang; Nanlin Yin; Hongbo Qi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.